Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Hypoglycemia · Diabetes Mellitus, Type 1 · XERS

Xeris Biopharma Holdings

Xeris Biopharma Holdings patent portfolio — 24 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Chicago, USA HQ
2005 Founded
496 Employees
Public company Type
XERS · NYSE Ticker
Company details
Status
Public
HQ
Chicago, USA
Founded
2005
Employees
496
Programs
16
Drugs
12
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Xeris Biopharma Holdings patents

24 pharmaceutical patents indexed for Xeris Biopharma Holdings. 0 expire within 24 months.

Xeris Biopharma Holdings has 24 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

24 patents

Patent portfolio

  1. US 12377096

    Methods of treating disease with levoketoconazole

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11964003

    Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11957736

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11833157

    Precipitation resistant small molecule drug formulations

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11590205

    Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11576951

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11446310

    Stable formulations for parenteral injection of small molecule drugs

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11129940

    Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11020403

    Precipitation resistant small molecule drug formulations

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10987399

    Stable formulations for parenteral injection of peptide drugs

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10765683

    Stable formulations for parenteral injection of small molecule drugs

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10485850

    Methods for producing stable therapeutic formulations in aprotic polar solvents

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9649364

    Methods for producing stable therapeutic formulations in aprotic polar solvents

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9642894

    Compositions for rapidly treating severe hypoglycemia

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9339545

    Stable formulations for parenteral injection of peptide drugs

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9314424

    Pastes for injection of a therapeutic agent

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9302010

    Stable formulations for parenteral injection of peptide drugs

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9295724

    Stable formulations for parenteral injection of peptide drugs

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9138479

    Formulations for the treatment of diabetes

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9125805

    Stable formulations for parenteral injection of small molecule drugs

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9018162

    Methods for rapidly treating severe hypoglycemia

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8790679

    Intracutaneous paste composition

    Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8697644

    Stable formulations for parenteral injection of peptide drugs

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8110209

    Intracutaneous injection

    Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Xeris Biopharma Holdings have?

24 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Xeris Biopharma Holdings patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.